CEO David DeStefano highlighted Vertex's strong start to 2025, reporting $177.1 million in revenue, a 12.9% year-over-year increase, supported by 14.4% growth in subscription revenue and 29.6% growth ...
After posting a disappointing forecast for 2017, Vertex is consolidating its R&D operations, according to a securities filing. The company plans to close a site in Canada, cutting 70 jobs, and trimmed ...
BMO Capital Markets analyst Daniel Jester reiterated the Market Perform rating on Vertex, Inc. (NASDAQ:VERX), raising the price target to $28 from $24. Investors rewarded the consistent execution ...
On the heels of Vertex Pharmaceuticals' ($VRTX) big news last week about changing CEOs next year, FierceBiotech chatted with both current chief executive Matt Emmens ...
Vertex Pharmaceuticals Incorporated (VRTX) is a good speculative biotech play to look into. That's because it is doing well in the Cystic Fibrosis [CF] space. It will still continue to do well with ...
3D Systems, a 3D printer and additive manufacturing system company, said it will acquire Vertex-Global Holding in a deal that highlights how market players are increasingly targeting industries for ...
In another departure from its core focus on genetic medicines, Vertex Pharma has agreed a $4.9 billion purchase of Alpine Immune Sciences, adding a mid-stage drug candidate for kidney disease IgA ...
Vertex Pharmaceuticals opened its new San Diego research center Monday, starting a new chapter in a decades-long quest to not only treat but cure cystic fibrosis. In 18 years, three drugs for the lung ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback